Compounding For Lower Prices Not PBMs’ New ‘Game Plan,’ Lawmakers Told
Executive Summary
Pharmacy benefit manager trade group chief Mark Merritt says PBMs are not poised to broadly promote compounded drugs as cheaper alternatives to off-patent drugs with no generic competition.
You may also be interested in...
Compounded Pyrimethamine: 'Personalized Medicine' Or 'Unapproved Drug'?
Responding to the Express Scripts' deal to promote use of a compounded alternative to its drug, Turing says physicians shouldn't prescribe the compound, since it is an unapproved and unsafe drug. But the compounder, Imprimis, says each prescription is custom-made, making it a "personalized medicine."
Express Scripts Turns To Compounding To Fight High-Priced Off-Patent Drugs
Pharmacy benefit manager's anti-Daraprim effort signals new direction in pricing battles, but the strategy can only be used in limited circumstances.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.